Scientific Publications

Updated Results from the RUBY-3 Study of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in IgA Nephropathy

Updated Results from the RUBY-3 Study of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in IgA Nephropathy

Updated results of povetacicept, an enhanced dual BAFF/APRIL antagonist, in IgA nephropathy (RUBY-3)

Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis

Povetacicept(ALPN-303), a Potent Dual BAFF/APRIL Antagonist, Suppresses Disease in a Mouse Model of Autoimmune Encephalitis

Updated Results from the RUBY-3 Study of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in IgA Nephropathy

The Enhanced Dual BAFF/APRIL Inhibitor Povetacicept (TACI vTD-Fc; ALPN-303) More Potently Reduces Disease Activity in Murine Lupus Compared to CD20 Depletion and WT TACI-Ig, Associated with Greater End-Organ Distribution

Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis

Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303)

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Myasthenia Gravis and Other Antibody-Related Neurological Diseases

Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis

Clinical Pharmacokinetic/Pharmacodynamic Modeling of Povetacicept, a
Potent Dual BAFF/APRIL Antagonist, to inform Dose Selection in
Autoimmune Diseases

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Myasthenia Gravis (MG) and Other Antibody-Related Neurological Diseases

Clinical Pharmacokinetic/Pharmacodynamic Modeling of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, to Inform Dose Selection in Autoimmune Diseases

Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Autoimmune Cytopenias and Other Antibody-Related Diseases

A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus and Other B Cell-Related Disorders (RUBY-1)

A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept, a Potent
Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus

Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides

Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, & Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides

Early Clinical PK/PD Modeling and Simulation of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, to Support Clinical Trials in Multiple Autoantibody- and/or B Cell-Related Diseases

Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Blistering Diseases (RUBY-1)

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist that Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases

Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics, & Pharmacodynamics of ALPN-303, a Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Glomerulonephritides (GN)

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Inhibitor, in Adult Healthy Volunteers (RUBY-1)

ALPN-303, an Engineered Dual BAFF/APRIL Antagonist, Potently Inhibits Pathogenic Autoantibodies in Preclinical Models, with Corresponding Pharmacodynamic Activity in Humans

ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases

ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Autoimmune Diseases

B Cell Modulatory Variant TNF Receptor Domains (vTDs) Identified by Directed Evolution to Inhibit BAFF and APRIL, Alone or Combined with Variant Ig Domains (vIgD™) that Inhibit T Cell Costimulation, for the Treatment of Systemic Lupus Erythematosus and Other Severe Autoimmune Diseases

Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Costimulation Pathways in Systemic Lupus Erythematosus

Systemic Administration of Acazicolcept(ALPN-101), a Dual ICOS/CD28 Antagonist, Suppresses Ocular Inflammation in Rat Experimental Autoimmune Uveitis

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

ALPN-101 (ICOSL vIgD Fc), a Dual Antagonist of the ICOS and CD28 Costimulatory Pathways, for Treatment of Steroid Refractory Acute GVHD ( aGVHD ): Case Report

First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects

ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

A Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of ALPN-101, a First-In-Class Dual ICOS/CD28 Antagonist, in Healthy Volunteers (HV)

ALPN-101, A First-In-Class Dual ICOS/CD28 Antagonist, Demonstrates Efficacy In Patient-Derived PBMC In Vitro And In an In Vivo T Cell Transfer Model Of Chronic Inflammatory Bowel Disease (IBD)

An Open Label Study of ALPN-101, a First in Class Dual CD28/ICOS Antagonist, in Subjects with Steroid Resistant or Steroid Refractory Acute Graft Versus Host Disease (BALANCE)

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome and Systemic Lupus Erythematosus

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis

Protein Engineering by Directed Evolution to Derive ALPN-101, a Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD)-Fc Fusion Protein for the Treatment of Inflammatory Diseases

ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates Potent and Dose-Dependent Suppression of Graft vs. Host Disease (GvHD) in a Human/NSGTM Mouse Xenograft Model, with Activity Superior to CD28 or ICOS Single Pathway Antagonists

Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity

Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates In Vivo Efficacy in an Experimental Autoimmune Encephalomyelitis (EAE) Model

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of IgSF Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

TPS2683: Davoceticept (ALPN-202), a PD-L1-dependent CD28 Costimulator and Dual Checkpoint Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Malignancies (NEON-2)

2560: Dose Escalation of Davoceticept, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1)

Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

Development of a Clinical Ex Vivo Assay for the Assessment of Therapeutic CD28 Costimulatory Pathway Engagement

A Study of ALPN-202, a PD-L1-dependent CD28 Costimulator and Dual Checkpoint Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Malignancies (NEON-2)

First in Human Dose Escalation of ALPN-202, A Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1)

NEON-1: A First-in-Human Phase I Open-Label Study of ALPN-202, a Conditional CD28 Costimulatorand Dual Checkpoint Inhibitor, in Advanced Malignancies

Engineered Variant Domain Fusion Proteins Provide Checkpoint Inhibition and Tumor Antigen-Dependent CD28 Costimulation Resulting in Potent Anti-Tumor Immunity

NEON-1: A first in human phase I open label study of ALPN 202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Development of Novel Monoclonal Antibodies for the Robust Detection of CD28, CD80, and CD86 by Immunohistochemistry in Human Tumors

ALPN-202 Combines Checkpoint Inhibition with Conditional T Cell Costimulation to Overcome T Cell Suppression by M2c Macrophages and Improve the Durability of Engineered T Cell Anti-Tumor Responses

ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Utilizes Multiple Mechanisms to Elicit Potent Anti-Tumor Immunity Superior to Checkpoint Blockade

ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Enhances the Activity of Multiple Standard of Care Modalities

“Switch” Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells